Lupin Ltd — Capital/Financing Update 2021

Dec 3, 2021

December 3, 2021

Limited Department of Corporate Services, P. J. Towers, Dalal Street, Mumbai Samachar Marg, MUMBAI - 400 001.

National Stock Exchange of lndla Llmtted Exchange Plaza, Bandra Kurla Complex, Bondre (East), MUMBAI - 400 051.

Sub: Dlsclosurt pursugnt to Reaulatlon 30 of the SEii Cllstlna Obllgattons qnd Disclosure Rtqulrementsl RegulatlonJ. 2015.

Dear Sir/Madam,

Enclosed is a Press Release as regards the Company having entered Into an exclusive distribution and marketing agreement with Biomm SA in Brazil for biosimilar Pegfilgrastim In Brazil.

This may kindly be considered as a disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Thanking you,

FOii WPIN LIMITED

R.V.SATAM COMPANY SECRETARY (ACS• t t 973)

Encl-: a/a.

LUPIN LIMITED

BSE:500257 NSE: LUPIN REUTERS: LUPIN.BO BLOOMBERG: LPCIN

Lupin and Biomm Enter into a Distribution and Marketing Agreement for Pegfilgrastim in Brazil

Mumbai, Brazil, December 03, 2021: Global pharma major, Lupin Limited (Lupin) announced today that they have entered into an exclusive distribution and marketing agreement with Biomm SA in Brazil. Under the terms of agreement, Biomm will distribute and market biosimilar Pegfilgrastim in Brazil.

Lupin had earlier received the U.S. FDA acceptance of the Biologics License Application (BLA) for Its proposed biosimilar to Neulasta• (pegfilgrastim) through a filing using the 351{k) pathway.

Pegfilgrastim is indicated to reduce the duration of neutropenia and the Incidence of febrile neutropenia in patients receiving chemotherapy.

About Lupin

Lupin Is an Innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products and APls in over 100 markets In the U.S., India, South Africa and across Asia Pacific (APAC), Latin America (LATAM), Europe and Mlddle East regions.

The Company enjoys leadership position in the cardiovascular, anti-diabetic, and respiratory segments and has significant presence In the anti-infective, gastro-intestinal (GI), central nervous system (CNS) and women's health areas. Lupin Is the third largest pharmaceutlcal company In the U.S. by prescriptions. The company invested 9.6% of Its revenue on research and development In FY21.

Lupin has 15 manufacturing sites, 7 research centres, more than 20,000 professionals working globally, and has been consistently recognized as a 'Great Place to Work' in the Biotechnology & Pharmaceuticals sector.

Please visit www.lupin.com for more information.

Follow us on Twitter: https://twitter.com/LueinGlobal I Llnkedln: https://www.llnkedin.com/companv/lupin Facebook: htto://www.facebook.com/LupinWorld/

AboutBlomm

Biomm's mission is to develop, produce and market global competitive biopharmaceuticals with quality and accessibility. The company's focus Is developing biological products, aiming to guarantee national selfsufficiency. Due to its innovator DNA, the company is pioneer in biotechnological drugs In Brazll. Founded in 2002, Biomm's headquarters and factory are in Nova Lima (MG), with capacity to produce 20 mlllion vials of insulin per year, based on advanced and innovative technologies that guarantee the medicines quality. The company Is listed on the Brazilian stock exchange (BVMF: BIOM3). For further information access www.biomm.com

BSE:S00257 NSE: LUPIN REUTERS: LUPIN.BO

BLOOMBERG: LPCIN

For further Information or queries please contact-

Shweta MunJal Vice President & Global Head - Corporate Communications Email: shwetamunral@lupin.com